

DAFTAR PUSTAKA

1. Silitonga YAM, Kurniati I. Kolaborasi Tuberculosis (TBC) dan Human Immunodeficiency Virus (HIV). *Medula* [Online]. 2019;9(1):276. Dari: <https://doi.org/10.53089/medula.v9i2.269> [7 Januari 2024]
2. Xi Y, Zhang W, Qiao RJ, Tang J. Risk Factors for Multidrug-Resistant Tuberculosis: A Worldwide Systematic Review and Meta-Analysis. *PLoS One* [Online]. 2022;17(6):1–15. Dari: <https://doi.org/10.1371/journal.pone.0270003> [18 Januari 2024]
3. Kurniawati E, Sulistyorini L. Analisis Kualitas Fisik Rumah Dengan Keberadaan Myobacterium Tuberculosis di Udara. *The Indonesian Journal Public Health* [Online]. 2018;13(1):14. Dari: <https://www.academia.edu/download/59430605/7234-37895-4-PB20190528-121651-1q1a8a2.pdf> [9 Januari 2024]
4. Rismawandi. Literature Review: Perbandingan Hasil Tes Cepat Molekuler (TCM) Kultur dan Metode Loop-Mediated Isothermal Amplification (LAMP) Dalam Mendeteksi Myobacterium Tuberculosis [Skripsi]. Yogyakarta: Universitas 'Aisyiyah; 2022.
5. Hartatik. Diagnosa Jenis Tuberculosis Dengan Algoritma Bayes. Konferensi Nasional Sistem & Informatika. Conference Paper [Online]. 2015;630. Dari: <https://www.neliti.com/publications/171923/diagnosa-jenis-tuberculosis-dengan-algoritma-bayes> [9 Januari 2024]
6. World Health Organization. *Global Tuberculosis Report 2020*. Geneva: World Health Organization; 2021
7. Republik Indonesia. *Profil Kesehatan Indonesia Tahun 2021*. Jakarta; Kementerian Kesehatan. 2022
8. Mashidayanti A, Nurlily, Kartinah N. Faktor Risiko yang Berpengaruh Pada Kejadian Tuberkulosis dengan Multidrug-Resistant Tuberculosis (MDR-TB) di RSUD Ulin Banjarmasin. *Jurnal Pharmascience* [Online]. 2020;07(02):140. Dari: <https://repo-dosen.ulm.ac.id/handle/123456789/19373> [18 Januari 2024]
9. Buryanti S, Fibriana AI. Faktor-Faktor yang Mempengaruhi Kejadian TB MDR di Kota Semarang. *Journal Health and Science* [Online]. 2021;5(1):147. Dari: <https://doi.org/10.35971/gojhes.v5i1.9699> [18 Januari 2024]
10. Sibuea CV, Pardosi MO, Simbolon IM, Adventus Tampubolon P. Polimorfisme Gen Vitamin D Receptor (VDR) BsmI pada Multi Drug Resistant Tuberculosis (MDR TB). *NJM* [Online]. 9(1):2023. Dari: <https://repository.uhn.ac.id/handle/123456789/8853> [15 Maret 2024]
11. Republik Indonesia. *Profil Kesehatan Indonesia Tahun 2020*. Jakarta; Kementerian Kesehatan. 2021
12. Sari SK, Krianto T. Faktor Pasien Drop Out Pengobatan Tuberkulosis di Indonesia: Tinjauan Sistematis. *Jurnal Kesehatan Masyarakat Aceh* [Online]. 2020;6(2):116. Dari: <https://doi.org/10.37598/jukema.v6i2.902> [18 Januari 2024]

13. Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 tentang Penanggulangan Tuberkulosis. Jakarta; Kementerian Kesehatan. 2016
14. World Health Organization. Global Tuberculosis Report 2017. Geneva: World Health Organization; 2018
15. Albaihaqi NA, Burhanuddin, Latuconsina VZ. Karakteristik Pasien Tuberkulosis Paru dengan Multidrug-Resistant (TB MDR) di RSUD Dr. M. Haulussy Ambon Tahun 2014-2018. *Pattimura Medical Review* [Online]. 2020;2(2):92. Dari: <https://doi.org/10.30598/pamerivol2issue2page90-102> [19 Januari 2024]
16. World Health Organization. Global Tuberculosis Report 2018 (Vol. 63). Geneva: World Health Organization; 2020
17. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M. The Epidemiology, Pathogenesis, Transmission, Diagnosis, And Management of Multidrug-Resistant, Extensively Drug-Resistant, and Incurable Tuberculosis. *National Library of Medicine* [Online]. 2017;1(5):291–360. Dari: <https://pubmed.ncbi.nlm.nih.gov/28344011/> [20 Januari 2024]
18. World Health Organization. Global Tuberculosis Report 2023. Geneva: World Health Organization; 2023
19. Gandra S, Tseng KK, Arora A, Bhowmik B, Robinson ML, Panigrahi B. The Mortality Burden of Multidrug-resistant Pathogens in India: A Retrospective, Observational Study. *National Library of Medicine* [Online]. 2019; 15;69(4):563–70. Dari: <https://pubmed.ncbi.nlm.nih.gov/30407501/> [19 Januari 2024]
20. Xie Y, Han J, Yu W, Wu J, Li X, Chen H. Survival Analysis of Risk Factors for Mortality in a Cohort of Patients with Tuberculosis. *Can Respir J*. 2020;1-9. Dari: <https://doi.org/10.1155/2020/1654653> [18 April 2024]
21. Paulus IB, Sanjay F, Sukmawati NMDD. Survival Rate of Multi-Drug Resistant Tuberculosis Among Human Immunodeficiency Virus Co-Infected Patients in Sanglah Hospital/Udayana University, Bali, Indonesia: A Cohort Retrospective Study. *International Journal of HIV-Related Problems* [Online]. 2021;20(2):109–13. Dari: <https://doi.org/10.5114/hivar.2021.107237> [23 Januari 2024]
22. Teweldemedhin M, Asres N, Gebreyesus H, Asgedom SW. Tuberculosis-Human Immunodeficiency Virus (HIV) co-infection in Ethiopia: A Systematic Review and Meta-Analysis. *National Library of Medicine* [Online]. 2018; 18;18(676):2–9. Dari: <https://pubmed.ncbi.nlm.nih.gov/30563476/> [13 Januari 2024]
23. Republik Indonesia. Tuberkulosis di Indonesia 2020-2024. Jakarta; Kementerian Kesehatan. 2020
24. Republik Indonesia. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia. Jakarta; Kementerian Kesehatan. 2020
25. Kementerian Kesehatan Republik Indonesia. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. Jakarta; 2023

26. Faralina M, Wahyono TYM, Wijaya F. Tinjauan Literatur: Keterlambatan Memulai Pengobatan Sebagai Salah Satu Faktor Risiko Hasil Akhir Pengobatan Tuberkulosis yang Buruk. *Jurnal Mandalika Cahaya* [Online]. 2020;3(2). Dari: <https://www.ojs.cahayamandalika.com/index.php/jcm/article/view/2510> [18 April 2024]
27. Kristina Y, Nurfaizah DA, Suweni K, Sinaga E, Riana D, Agussalim. Studying Patient Attitudes and Family Support in The Perspective of Ro Tb Patients' Medication Compliance in Jayapura City. *Journal of Clinical Nursing & Reports* [Online]. 2023;2(4):1–10. Dari: https://www.researchgate.net/publication/376410452_Issue_2_1_of_9_Int_J_Family_Med_Healthcare_2023_4_Parepare_School_of_Nursing [18 April 2024]
28. Republik Indonesia. Kasus MDR-TB Tahun 2020-2022 Provinsi Sumatera Barat. Padang; Dinas Kesehatan Provinsi Sumatera Barat. 2022
29. Republik Indonesia. Data Kasus MDR-TB Tahun 2020-2023 RS Paru Sumbar. Padang Pariaman; Rumah Sakit Paru Sumatera Barat. 2024
30. Wang J, Zhou M, Chen Z, Chen C, Wu G, Zuo Y. Survival of Patients with Multidrug-Resistant Tuberculosis in Central China: A Retrospective Cohort Study. *National Library of Medicine* [Online]. 2020;1–6. Dari: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078509/> [19 Januari 2024]
31. Adamu AL, Gadanya MA, Abubakar IS, Jibo AM, Bello MM, Gajida AU. High mortality Among Tuberculosis Patients on Treatment in Nigeria: A Retrospective Cohort Study. *National Library of Medicine* [Online]. 2017; 23;17(170):8. Dari: <https://pubmed.ncbi.nlm.nih.gov/28231851/> [20 Januari 2024]
32. Getahun GK, Gezahegn E, Endazenawe G, Shitemaw T, Negash Z, Dessu S. Survival Status and Risk Factors for Mortality Among Multidrug-Resistant Tuberculosis Patients in Addis Ababa, Ethiopia: A Retrospective follow-up Study. *J Clin Tuberc Other Mycobact Dis* [Online]. 2023;1(33):4. Dari: <https://pubmed.ncbi.nlm.nih.gov/37767135/> [19 Januari 2024]
33. Fantaw D, Feyissa M, Hamid S, Shibeshi W. Assessment of the Survival Status and Risk Factors for the Mortality among Multidrug Resistant Tuberculosis Patients at Adama and Bishoftu General Hospitals, Oromia, Ethiopia: A Retrospective Cohort Study. *Advances Pharmacoepidemiology & Drug Safety* [Online]. 2018;7(1):5. Dari: <https://www.researchgate.net/publication/335632104> [19 Januari 2024]
34. Kassa GM, Woldetsadik AT, Gelaw YA, Alemayehu TT, Tsegaye AT, Tamirat KS. Predictors of Mortality Among Multidrug-Resistant Tuberculosis Patients in Central Ethiopia; a Retrospective Follow-Up Study. *Epidemiol Infect* [Online]. 2020;5. Dari: <https://doi.org/10.1017/S0950268820002514> [19 Januari 2024]
35. Mulugeta SS, Tamiru SD, Sultan HH, Zerihun Z, Tadele G, Teklu T. Survival and Predictors of Mortality from Multidrug Resistant Tuberculosis (MDR-TB) Among Patients Treated at MDR-TB Referral Hospitals in Ethiopia: A Retrospective Cohort Study. *J Public Health Epidemiol* [Online]. 2020; 31;12(1):19. Dari: <https://doi.org/10.5897/JPHE2019.1129> [19 Januari 2024]

36. Ayuningsih Z, Yunis T, Wahyono M. Faktor yang Berhubungan dengan Kematian Pasien TB MDR Selama Masa Pengobatan di Indonesia Tahun 2015-2017. *Pro Health Jurnal Ilmiah Kesehatan* [Online]. 2019;1(2):41–7. Dari: <https://jurnal.unw.ac.id/index.php/PJ/article/view/41-48/pdf> [18 April 2024]
37. Firnawati AF, Ahmad RA, Retnowulan H. Ketahanan hidup dua tahun pasien tuberkulosis resisten obat di RS. Moewardi Surakarta tahun 2010-2014. *Berita Kedokteran Masyarakat* [Online]. 2017;33(8):371–6. Dari: <https://doi.org/10.22146/bkm.22462> [24 Januari 2024]
38. Tiberi S, Utjesanovic N, Galvin J, Centis R, D'Ambrosio L, Boom M van Den. Drug Resistant TB – Latest Developments in Epidemiology, Diagnostics and Management. *International Journal of Infectious Diseases* [Online]. 2022; 1(124): 21. Dari: <https://doi.org/10.1016/j.ijid.2022.03.026> [20 Januari 2024]
39. World Health Organization. *Global Tuberculosis Report 2021*. Geneva: World Health Organization; 2022
40. Miggiano R, Rizzi M, Ferraris DM. Mycobacterium Tuberculosis Pathogenesis, Infection Prevention and Treatment. *Pathogens* [Online]. 2020;9(5):385. Dari: <https://doi.org/10.3390/pathogens9050385> [20 Januari 2024]
41. Rita E, Qibtiyah SM. Hubungan Kontak Penderita Tuberkulosis Terhadap Kejadian Tuberkulosis Paru Pada Anak. *Indonesian Journal of Nursing Science and Practice* [Online]. 2020;3(1):39. Dari: <https://doi.org/10.24853/ijnsp.v3i1.35-41> [21 Januari 2024]
42. Reviono, Kunanto P, Eko V, Pakiding H, Nurwidiasih D. Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. *Bandung Medical Journal* [Online]. 2014;46(4). Dari: <http://dx.doi.org/10.15395/mkb.v46n4.336> [20 Januari 2024]
43. World Health Organization. *Companion Handbook “to the WHO Guidelines for The Programmatic Management of Drug-Resistant Tuberculosis.”* Geneva; 2018
44. Bloss E, Kuksa L, Holtz T, Riekstina V, Skripconoka V, Kammerer S. Adverse Events Related to Multidrug-Resistant Tuberculosis Treatment, Latvia, 2000-2004. *National Library of Medicine* [Online]. 2010;14(3). Dari: <https://pubmed.ncbi.nlm.nih.gov/20132617/> [20 Januari 2024]
45. Monedero I, Caminero JA. Management of Multidrug-Resistant Tuberculosis: an Update. *National Library of Medicine* [Online]. 2010;4(2). Dari: <https://doi.org/10.1177/1753465810365884> [20 Januari 2024]
46. Sutrisna M, Rahmadani E. Hubungan Usia dan Jenis Kelamin dengan TB MDR. *SEHATRAKYAT (Jurnal Kesehatan Masyarakat)* [Online]. 2022;1(4):373. Dari: <https://doi.org/10.54259/sehatrakyat.v1i4.1168> [21 Januari 2024]
47. Bijawati E, Amansyah M, Nurbiah. Faktor Risiko Pengobatan Pasien Multidrug Resistance Tuberculosis (MDR-TB) di RSUD Labuang Baji Kota Makassar Tahun 2017. *Jurnal Nasional Ilmu Kesehatan (JNIK)* [Online]. 2018;15–11. Dari: <https://journal.unhas.ac.id/index.php/jnik/article/view/4282> [21 Januari 2024]

48. Arifah N, Sukartini T, Harmayetty. Karakteristik Pasien Multidrug Resistant Tuberculosis (MDR-TB) di RSUD Makassar. *Journal of Health Research "Forikes Voice"* [Online]. 2019;27;10(4):256. Dari: <http://dx.doi.org/10.33846/sf10401> [22 Januari 2024]
49. Santy D, Siagian P, Sinaga BYM, Eyoanoer PC. Hubungan Indeks Massa Tubuh dengan Waktu Konversi Sputum Pada Pasien TB MDR yang Menjalani Pengobatan dengan Panduan Jangka Pendek di RSUP H. Adam Malik Medan [Skripsi]. Medan: Universitas Sumatera Utara. 2014
50. Sulistyowati E. Gambaran Lingkungan Fisik dan Status Gizi Penderita Tuberculosis Paru di Poli Paru RSUD Ngudi Waluyo Wlingi Periode Desember 2014. *Journal of Ners and Midwifery* [Online]. 2015;1;2(3):253. Dari: <https://doi.org/10.26699/jnk.v2i3.ART.p248-254> [21 Januari 2024]
51. Wianti A. Hubungan Dukungan Keluarga dengan Kepatuhan Minum Obat Pada Pasien Tuberculosis Paru di Puskesmas Kaladawa Kabupaten Tegal Tahun 2017. *Jurnal Kampus STIKES YPIB Majalengka* [Online]. 2018;7(14):10. Dari: <https://doi.org/10.51997/jk.v7i1.57> [21 Januari 2024]
52. Niazi AK, Kalra S. Diabetes and Tuberculosis: A review of The Role of Optimal Glycemic Control. *J Diabetes Metab Disord* [Online]. 2012;20;11(28):1–4. Dari: <https://link.springer.com/article/10.1186/2251-6581-11-28> [21 Januari 2024]
53. Rahman DW, Apriliana E. Peningkatan Risiko infeksi Multi Drugs Resistant Tuberculosis (MDR-TB) pada Penderita Human Immunodeficiency Virus (HIV). *Majority* [Online]. 2020;9(2):168. Dari: <https://joke.kedokteran.unila.ac.id/index.php/majority/article/view/2859> [22 Januari 2024]
54. Zhang Q, Wu Z, Zhang Z, Sha W, Shen X, Xiao H. Efficacy and Effect of Free Treatment on Multidrug-Resistant Tuberculosis. *Exp Ther Med* [Online]. 2016;1;11(3):777–82. Dari: <https://doi.org/10.3892/etm.2015.2966> [22 Januari 2024]
55. Limenih YA, Workie DL. Survival Analysis of Time to Cure on Multi-drug Resistance Tuberculosis Patients in Amhara Region, Ethiopia. *BMC Public Health* [Online]. 2019;7;19(1). Dari: <https://link.springer.com/article/10.1186/s12889-019-6500-3> [22 Januari 2024]
56. Indra Yani D, Juniarti N, Lukman M. Characteristics of Multidrug-Resistant Tuberculosis and Smear-Positive Pulmonary Tuberculosis: A Case-Referent Study. *Malaysian Journal of Medicine and Health Sciences* [Online]. 2022;18(2):40. Dari: https://medic.upm.edu.my/upload/dokumen/202201260949438_0737.pdf [22 Januari 2024]
57. Rahmanika FA, Purnami SW, Kusumawardani NA. Analisis Kurva Survival Kaplan Meier pada Pasien HIV/AIDS dengan Antiretroviral Therapy (ART) di RSUD Prof. Dr. Soekandar Kabupaten Mojokerto Menggunakan Uji Log Rank. *Jurnal Sains dan Seni ITS* [Online]. 2016;5(1):128. Dari: <http://dx.doi.org/10.12962/j23373520.v5i1.14995> [23 Januari 2024]
58. Republik Indonesia. Peraturan Menteri Kesehatan Nomor 41 tahun 2014 tentang Pedoman Gizi Seimbang. Jakarta; Kementerian Kesehatan. 2014

59. Pranita KR, Kristanti FT. Analisis Financial Distress Menggunakan Analisis Survival. Nominal: Barometer Riset Akuntansi dan Manajemen [Online]. 2020;9(2):247. Dari: <http://dx.doi.org/10.21831/nominal.v9i2.30917> [21 Januari 2024]
60. Dahlan MS. Analisis Survival: Dasar-Dasar Teori & Aplikasi Dengan Program SPSS (11th ed). Jakarta Timur: PT. Epidemiologi Indonesia; 2021
61. Putra IW, Widarsa IKT, Astuti PAS. Modul Pelatihan Analisis Kesintasan Pada Penelitian Kesehatan dengan STATA [Online]. Fakultas Kedokteran Universitas Udayana, 2016. Dari: https://simdos.unud.ac.id/uploads/file_pendidikan_1_dir/05f2476461d95b45a7779308a683cdbc.pdf [26 Januari 2024]
62. Rich JT, Neely JG, Paniello RC, Voelker CCJ, Nussenbaum B, Wang EW. A Practical Guide to Understanding Kaplan-Meier Curves. National Institute of Health Public Access [Online]. 2010;143(3):333. Dari: <https://pubmed.ncbi.nlm.nih.gov/20723767/> [26 Januari 2024]
63. Suhartini A, Rahmawati R, Suparti. Analisis Survival Kaplan-Meier Menggunakan Uji Log Rank (Studi Kasus: Pasien Penyakit Jantung Koroner di RSUD Undata Palu). Jurnal Gaussian [Online]. 2018;7(1):33. Dari: <https://doi.org/10.14710/j.gauss.7.1.33-42> [26 Januari 2024]
64. Yaghi AR, Shaheed HS, Harun SN, Hyder Ali IA, Khan AH. Survival Trend of Tuberculosis Patients and Risk Factors Associated with Mortality and Developing Drug-Resistant Tuberculosis in Hospital Pulau Pinang, Malaysia: a Retrospective Study. Adv Respir Med [Online]. 2022;90(6):467–82. Dari: <https://doi.org/10.3390/arm90060054> [2 Juni 2024]
65. Balabanova Y, Radiulyte B, Davidaviciene E, Hooper R, Ignatyeva O, Nikolayevskyy V, et al. Survival of Drug Resistant Tuberculosis Patients in Lithuania: Retrospective National Cohort Study. BMJ Open Medical Research [Online]. 2011;1(2). Dari: <https://doi.org/10.1136/bmjopen-2011-000351> [2 Juni 2024]
66. Khan MA, Mehreen S, Basit A, Khan RA, Javaid A. Predictors of Poor Outcomes among Patients Treated for Multidrug-Resistant Tuberculosis at Tertiary Care Hospital in Pakistan. Journal of Toxicological Sciences [Online]. 2015;7(3):162–72. Dari: <https://doi.org/10.1016/j.tube.2012.06.003> [6 Juni 2024]